UCT and CPGR join forces with international Pharmacogenomics initiative focussing on African diseases.
17 June 2011, Cape Town, South Africa Tweet
The Division of Human Genetics at the University of Cape Town (UCT) and the Centre for Proteomic and Genomic Research (CPGR), Cape Town, South Africa, proudly announce that they will be joining the 'Pharmacogenomics for Every Nation Initiative' (PGENI). Jointly, the two parties will form a South African PGENI Centre of Competence for conducting translational research relevant to the local burden of disease and the most appropriate drugs for treating diseases in African populations.
CPGR joins the Proteomics Innovation Network (PIN) of Service and Product Providers
24 May 2011. Cape Town, South Africa
The Centre for Proteomic & Genomic Research (CPGR) is proud to announce that it has joined
the thirteen international proteomics service and product providers that form the Proteomics
Innovation Network. The mission of the Proteomics Innovation Network is to generate "from sample to discovery"
solutions in all facets of proteomics, including expression, identification, characterization,
interaction and function.
SimuGen Completes a Major R&D Programme with Partner Company CPGR
16 September 2010. London (UK) and Kuala Lumpur (Malaysia)
SimuGen, a discovery pharmacogenomics company focused on predicting human toxicity early on in drug development, announced today that it has completed a major R&D programme with its partner; The
Centre for Proteomic and Genomic Research (CPGR) in South Africa. This paves the way for a launch later this month, of SimuGen's flagship discovery pharmacogenomics software HT-Stream.
CPGR and UCB scientists look for biomarkers to enhance influenza vaccination programs
17 June 2010, Cape Town, South Africa
CPGR (Cape Town, South Africa) today announced that it is teaming up with scientists at UBC (University of British Columbia, Vancouver, Canada) in a quest to identify immune correlates of response to
vaccination in patients treated with seasonal influenza vaccines. In the biomarker discovery project, the CPGR will heavily rely on its comprehensive expertise in developing multiplex protein
array-based antibody profiling assays and related computational solutions for enhanced bioinformatic data-analysis.
CPGR to develop novel food quality assurance technology with Verified
11 June 2010. Cape Town, South Africa
CPGR (CT, South Africa) today announced that it has commenced the development of a meat quality control assay based on multiplex PCR in a project commissioned by South African based Verified
Technologies. In the project, the Centre will use its expertise in nucleic acid (NA) based applications to develop and validate a portfolio of assays aimed at correlating the integrity of DNA
molecules with the quality of processed meat
CPGR hits major milestone in drug toxicology study with SimuGen
27 April 2010, Cape Town, South Africa
CPGR (CT, South Africa) today announced that it has achieved a major milestone in a research project contracted by SimuGen Asia Sdn. Bhd. (KL, Malaysia), successfully completing a series of drug
toxicity screens in cultured human liver cells (HepaRG) and on Affymetrix Gene ST Arrays as part of the development of an in vitro dose-response model of human toxicity.
FIND to join CPGR as a member in its effort to develop a leading biotech hub in South Africa
06 May 2009, Cape Town, South Africa
CPGR (Cape Town, South Africa) today announced that FIND (Foundation for Innovative New Diagnostics) (Geneva, Switzerland) has joined the organization as a member. The concept of common ownership of
the CPGR is unique since, unlike shareholders in a for-profit company, as a non-for-profit organization (incorporated in South Africa under Section 21) the CPGR is "owned" by its Membership.
South Africa's CPGR turns to cell-culture based screening to advance drug discovery & development
19 March 2009, Cape Town, South Africa
CPGR (CT, South Africa) today announced that it has entered into an agreement with SimuGen (KL, Malaysia), involving the development of novel biomarker assays for the prediction of toxicity of
existing and novel drug compounds.
South African Core Lab Adopts Affymetrix Technology For Genomic Studies
7 October 2008, Santa Clara, Calif
Affymetrix Inc., (Nasdaq: AFFX) today announced that one of South Africa’s largest public core labs has begun offering genomic research on the Affymetrix GeneChip® platform. The Centre for
Proteomic and Genomic Research (CPGR) is using many Affymetrix GeneChip arrays, such as the exon array and the SNP Array 6.0, to explore applications with molecular diagnostics potential, large-scale
genotyping and novel ways of advancing drug research and development across the country.
Centre for Proteomic and Genomic Research and CapitalBio Corporation to collaborate in the field of Genomic Medicine and Biomarker Discovery
09 September 2008, Beijing, China and Cape Town, RSA
The Centre for Proteomic and Genomic Research (CPGR), a South African Government sponsored, not for profit, core technology facility in Cape Town, South Africa, and CapitalBio (CB), a leading biotech
company in Beijing, China, announce that they are entering into a mutual agreement in the field of Genomic Medicine and Biomarker Discovery.
Gentel Biosciences places first protein array reader at CPGR, South Africa
19 August 2008, Madison WI and Cape Town, RSA
Gentel® Biosciences, Inc., a protein microarray life sciences company, announces it has placed its first APiX™ Colorimetric Protein Array Reader at the Centre for Proteomic and Genomic
Research (CPGR) in Cape Town, South Africa.
Press Releases
